{"summary":"As an optimist, I believe together we have the power to help patients live longer better lives.\n\n\ud83e\udd7c As an accomplished clinical pharmacologist with 12 years of experience in clinical research, I bring a unique blend of strategic vision, medical expertise, and leadership acumen to drive impactful results in a dynamic healthcare landscape.\n\n\ud83d\udc8a Throughout my career, I have successfully develop and execute clinical pharmacology strategies to ensure a better understanding of medicines and their interactions with the body that drive better outcome for patients. \n\n\ud83e\udd7c  My deep understanding of medical science, coupled with a strong understanding of clinical development, has enabled me to navigate complex challenges and deliver innovative solutions that meet both scientific and business objectives.\n\n\ud83e\udd1d I excel in fostering strong collaborative relationships with key stakeholders, including healthcare providers, and internal teams, to ensure alignment and drive towards shared goals. My ability to effectively communicate complex medical information to diverse audiences has been instrumental in building trust and credibility with HCPs and management stakeholders.\n\n\ud83c\udfaf Moreover, my strategic mindset and analytical prowess have consistently allowed me to adapt to changing situations, identify opportunities, and mitigate risks effectively. I thrive in fast-paced environments, where I can leverage my problem-solving skills to address challenges head-on and drive continuous improvement.\n\n I am passionate about leveraging my expertise and leadership capabilities to help my team, driving innovation, and ultimately improving patient outcomes.\n\n\n\u2022I have extensive working knowledge of multiple therapeutic areas and modalities (small and large molecules, mAb, ADC, peptides) from discovery to post launch.\n\n\u2022Clinical expertise | Experience in the care of patients | Multidisciplinary team  | Strategic thinking | Oral and written communication  | Clinical Pharmacology | Pharmacokinetics & Pharmacodynamics | Clinical & Preclinical Development |  \n\n\u2022Therapeutic Area: Oncology  | Infectious diseases | Respiratory Diseases |  Immunosuppression |\n Neurology\n\n\u2709\ufe0f If you\u2019re curious, you can read my manuscripts at https:\/\/www.researchgate.net\/profile\/Riff_Camille","lastName":"Riff","objectUrn":"urn:li:member:342487366","geoRegion":"Gothenburg, V\u00e4stra G\u00f6taland County, Sweden","fullName":"Camille Riff","firstName":"Camille","currentPositions":[{"companyName":"AstraZeneca","description":"Support the early phase Respiratory portfolio as a clinical pharmacology lead for inhaled, oral and IV, small and large drug candidates\n\nDevelop, implement and deliver the clinical pharmacology and pharmacometrics strategy, including clinical study design and protocol development, ICF, data analysis and interpretation, contribution to and participation in regulatory interactions, submissions and review, paediatric development and life cycle management.\n\u2022\tPresenter at governance interactions including Clinical Pharmacology Review Board, Clinical Review Committee, Research Board, PH2 Investment Decision, presenter at interactions with KEEs. \n\u2022\tEstablishing relationship with key stakeholders in early R&I organisation, developing a network with various functions within early phase R&I organisation, key member of the clinical team, close partner with the DMPK lead and pharmacometricians \n\u2022\tTrough scientific leadership, seek opportunities to take strategic or model-based approaches to simplify ways of working, highlighting participants burden, cost and time saving in the process\n\u2022\tKey driver of quantitative approaches to support paediatric strategy\n\u2022\tCollaborate with academic group to provide Clinical Pharmacology expertise and maximize chance to fulfill study objectives\n\nKey achievements: \n\u2022\tPresenter in interaction with FDA and EMA as part of a PSA, KEEs\n\u2022\tWinner of Inclusion & diversity Award\n\u2022      Nominated as Exceptional contributor in 2023","title":"Associate Director, Clinical Pharmacology & Quantitative Pharmacology","companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"geographicArea":"Cambridgeshire","country":"United Kingdom","city":"Cambridge","postalCode":"CB2 0AA","line2":"Cambridge Biomedical Campus","line1":"1 Francis Crick Avenue"},"website":"http:\/\/www.astrazeneca.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/astrazeneca\/","industry":"Pharmaceutical Manufacturing"},"companyUrn":"urn:li:fs_salesCompany:1603","tenureAtCompany":{"numYears":2,"numMonths":5},"startedOn":{"month":1,"year":2022}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1671635882104?e=1723075200&v=beta&t=CnoOiVeqKXjXGjsEZDRx0D-tfdjD3uOBEC3IQgUl3TI","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1671635882104?e=1723075200&v=beta&t=O-mfatFpS0mQlz1I5CHRdtQP3qecFHiyItBQfxaFXUI","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1671635882104?e=1723075200&v=beta&t=ytOOo00o4GEe0dda3YXS8HLni4eOB0ppgh9eUXuOaic","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1671635882104?e=1723075200&v=beta&t=gSPWjDK7-5Ez8Q4xsNkyTg706523yPtYVM6-xySWaLw","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E03AQFKy7jY_ssngQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{"websites":[{"$anti_abuse_annotations":[{"attributeId":97,"entityId":19,"sourceUrn":"urn:li:member:342487366"},{"attributeId":48,"entityId":19,"sourceUrn":"urn:li:member:342487366"}],"category":"OTHER","dataSource":"LINKEDIN","url":"https:\/\/www.researchgate.net\/profile\/Riff_Camille"}]},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2018},"degree":"Doctor of Philosophy (PhD)","eduId":306744702,"schoolUrn":"urn:li:fs_salesSchool:15250774","school":"urn:li:fs_salesSchool:15250774","fieldsOfStudy":["Pharmacometrics"],"schoolName":"Aix-Marseille Universit\u00e9","startedOn":{"year":2014}},{"endedOn":{"month":8,"year":2018},"eduId":702559728,"schoolUrn":"urn:li:fs_salesSchool:157321","school":"urn:li:fs_salesSchool:157321","fieldsOfStudy":["Uppsala Pharmacometrics Summer School"],"schoolName":"Uppsala University","startedOn":{"month":8,"year":2018}},{"endedOn":{"year":2016},"degree":"Doctor of Pharmacy (PharmD)","eduId":306749256,"schoolUrn":"urn:li:fs_salesSchool:15250774","school":"urn:li:fs_salesSchool:15250774","schoolName":"Aix-Marseille Universit\u00e9","startedOn":{"year":2015}},{"endedOn":{"month":4,"year":2016},"fieldsOfStudy":["5th Annual Individualized Therapeutic Approach group (ITAG) meeting"],"schoolName":"\tLaboratory of Applied Pharmacokinetics and Bioinformatics","startedOn":{"month":4,"year":2016},"eduId":702566148},{"endedOn":{"month":5,"year":2015},"eduId":702807163,"schoolUrn":"urn:li:fs_salesSchool:18423073","school":"urn:li:fs_salesSchool:18423073","fieldsOfStudy":["Statistics"],"schoolName":"Sorbonne Universit\u00e9","startedOn":{"month":9,"year":2014}},{"endedOn":{"year":2014},"degree":"Master's degree","eduId":219659045,"schoolUrn":"urn:li:fs_salesSchool:15250774","school":"urn:li:fs_salesSchool:15250774","fieldsOfStudy":["pharmacokinetics"],"schoolName":"Aix-Marseille Universit\u00e9","startedOn":{"year":2013}},{"endedOn":{"month":10,"year":2016},"eduId":702808054,"schoolUrn":"urn:li:fs_salesSchool:15250774","school":"urn:li:fs_salesSchool:15250774","fieldsOfStudy":["Pharmacy"],"schoolName":"Aix-Marseille University","startedOn":{"month":11,"year":2012}},{"endedOn":{"year":2012},"eduId":219659037,"schoolUrn":"urn:li:fs_salesSchool:15097682","school":"urn:li:fs_salesSchool:15097682","fieldsOfStudy":["Pharmacy"],"schoolName":"Universit\u00e9 de Strasbourg","startedOn":{"year":2007}}],"skills":[{"numOfEndorsement":0,"name":"Business Strategy"},{"numOfEndorsement":0,"name":"New Business Development"},{"numOfEndorsement":0,"name":"Clinical Pharmacy"},{"numOfEndorsement":0,"name":"Patient Education"},{"numOfEndorsement":0,"name":"Training"},{"numOfEndorsement":0,"name":"Educational Materials Development"},{"numOfEndorsement":0,"name":"Inpatient Care"},{"numOfEndorsement":0,"name":"Clinical Research"},{"numOfEndorsement":0,"name":"Cross-team Collaboration"},{"numOfEndorsement":0,"name":"Team Management"},{"numOfEndorsement":0,"name":"Stakeholder Relations"},{"numOfEndorsement":0,"name":"Strategic Planning"},{"numOfEndorsement":0,"name":"Teamwork"},{"numOfEndorsement":0,"name":"Interdisciplinary Collaboration"},{"numOfEndorsement":0,"name":"Management"},{"numOfEndorsement":0,"name":"Team Leadership"},{"numOfEndorsement":0,"name":"Analytical Skills"},{"numOfEndorsement":0,"name":"Critical Thinking"},{"numOfEndorsement":0,"name":"Cross-functional Team Leadership"},{"numOfEndorsement":1,"name":"Clinical Pharmacology"},{"numOfEndorsement":1,"name":"Pharmacometrics"},{"numOfEndorsement":1,"name":"Drug Development"},{"numOfEndorsement":0,"name":"Good Clinical Practice (GCP)"},{"numOfEndorsement":0,"name":"Clinical Trials"},{"numOfEndorsement":0,"name":"Oncology"},{"numOfEndorsement":1,"name":"Life Sciences"},{"numOfEndorsement":0,"name":"Written Communication"},{"numOfEndorsement":0,"name":"Oral Communication"},{"numOfEndorsement":0,"name":"Interpersonal Communication"},{"numOfEndorsement":0,"name":"Leadership Communications"},{"numOfEndorsement":0,"name":"Healthcare Information Technology (HIT)"},{"numOfEndorsement":0,"name":"Artificial Intelligence for Business"}],"pronoun":"She\/Her","numOfConnections":733,"patents":[],"headline":"Associate Director @ AstraZeneca | PharmD, PhD | Passion for Clinical Practice Optimization | Helping others improving patient's care","courses":[],"certifications":[{"endedOn":{"month":4,"year":2023},"companyUrn":"urn:li:fs_salesCompany:829701","url":"https:\/\/www.youracclaim.com\/badges\/03b11cff-0b63-4c02-a5ae-cbb2e11a1d7c\/linked_in_profile","authority":"Certara","name":"Certara Certified NCA Analyst using Phoenix WinNonlin Versions 8.1 and 8.2","company":"urn:li:fs_salesCompany:829701","startedOn":{"month":4,"year":2020}},{"endedOn":{"month":5,"year":2023},"companyUrn":"urn:li:fs_salesCompany:829701","url":"https:\/\/www.youracclaim.com\/badges\/7cc91213-f2c8-4bca-803c-7502198d97fc\/linked_in_profile","authority":"Certara","name":"Certara Certified Population PK\/PD Pharmacometrician (Level 1) using Phoenix NLME 8.0\/8.1\/8.2","company":"urn:li:fs_salesCompany:829701","startedOn":{"month":5,"year":2020}},{"companyUrn":"urn:li:fs_salesCompany:1337","url":"https:\/\/www.linkedin.com\/learning\/certificates\/edb57bf17909b2096a63196805726e38da2b30d522aa5cde082e9a3222cb424b","authority":"LinkedIn","name":"Interpersonal Communication (2020)","company":"urn:li:fs_salesCompany:1337","startedOn":{"month":7,"year":2023}},{"companyUrn":"urn:li:fs_salesCompany:12729","url":"https:\/\/www.credly.com\/badges\/a5f02e4f-2c60-4b06-8737-520274470d40\/linked_in_profile","authority":"Kobalt Media heet nu CaratNL","name":"MBA essential training course","company":"urn:li:fs_salesCompany:12729","startedOn":{"month":12,"year":2023}},{"companyUrn":"urn:li:fs_salesCompany:5383","url":"https:\/\/skillsoft.digitalbadges-eu.skillsoft.com\/4d1d4230-be20-4286-86fa-d84d3f541dc9","authority":"Skillsoft","name":"Transforming the Workplace Using Artificial Intelligence","company":"urn:li:fs_salesCompany:5383","licenseNumber":"7987462","startedOn":{"month":3,"year":2024}},{"companyUrn":"urn:li:fs_salesCompany:5383","url":"https:\/\/skillsoft.digitalbadges-eu.skillsoft.com\/a5741bf7-e4a7-4bb6-a17a-cbc1ab2d80ae","authority":"Skillsoft","name":"New Project Manager Essentials","company":"urn:li:fs_salesCompany:5383","licenseNumber":"8140147","startedOn":{"month":3,"year":2024}},{"companyUrn":"urn:li:fs_salesCompany:5383","url":"https:\/\/skillsoft.digitalbadges-eu.skillsoft.com\/dd179c92-a55d-4c48-9f88-834cab80ef86","authority":"Skillsoft","name":"Defining a Project Scope and Team","company":"urn:li:fs_salesCompany:5383","licenseNumber":"8145353","startedOn":{"month":3,"year":2024}},{"companyUrn":"urn:li:fs_salesCompany:1337","url":"https:\/\/www.linkedin.com\/learning\/certificates\/282f4e6fb89f9d622d1ba3f759ac8e2b89bfe67ddff5fcc2e9c665cbcb66350b","authority":"LinkedIn","name":"Improving Your Leadership Communications","company":"urn:li:fs_salesCompany:1337","startedOn":{"month":3,"year":2024}},{"companyUrn":"urn:li:fs_salesCompany:1337","url":"https:\/\/www.linkedin.com\/learning\/certificates\/0c1541510250a906215ebc7d95a0bd662170e50e2a3789723e6a55995e7270af","authority":"LinkedIn","name":"An Introduction to How Generative AI Will Transform Healthcare","company":"urn:li:fs_salesCompany:1337","startedOn":{"month":3,"year":2024}},{"companyUrn":"urn:li:fs_salesCompany:5383","url":"https:\/\/skillsoft.digitalbadges-eu.skillsoft.com\/3cf00365-0503-42f0-85a3-e266cd806aeb","authority":"Skillsoft","name":"Leading in the Age of Generative AI","company":"urn:li:fs_salesCompany:5383","licenseNumber":"8367214","startedOn":{"month":4,"year":2024}}],"memberBadges":{"premium":true,"openLink":true,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/camilleriff","organizations":[],"location":"Gothenburg, V\u00e4stra G\u00f6taland County, Sweden","publications":[{"name":"Prolonged continuous wound infiltration with a local anaesthetic after total mastectomy: pharmacokinetics and preliminary results on postoperative pain","publishedOn":{"month":10,"day":4,"year":2018},"publisher":"Anaesth Crit Care Pain Med.","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30292487","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":6,"day":16,"year":2018},"description":"Tumescent lidocaine anesthesia (TLA) is an opportunity to perform mastectomy for breast cancer without general anesthesia in elderly women. \n\nPopulation PK model of lidocaine after TLA  (NONMEM)\n- to describe a technique never described before \n- to explore the risk of the toxicity (directly related to plasma level) of this technique\n\n","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29909577","name":"Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery.","publisher":"Eur J Clin Pharmacol. ","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"name":"Tumescent local anaesthesia for breast cancer surgery in elderly women: about 6 cases.","publishedOn":{"month":6,"day":1,"year":2018},"publisher":"Anaesth Crit Care Pain Med. ","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29864551","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":4,"day":16,"year":2018},"description":"Ropivacaine continuous wound infusions (CWIs) are extensively used as a component of multimodal analgesia. \n\nPopulation pharmacokinetic (popPK) analysis (NONMEM): \n- to describe the pharmacokinetics of ropivacaine CWI during 75 hours\n- to investigate the risk of potential systemic toxicity in the context of in-home recovery and post-operatory care\n","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29659182","name":"Ropivacaine Wound Infiltration for Pain Management After Breast Cancer Mastectomy: A Population Pharmacokinetic Analysis.","publisher":"Clin Pharmacol Drug Dev.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"name":"What can we expect from clinical trials in psychiatry?","publishedOn":{"month":12,"year":2016},"publisher":"Encephale.","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28236988","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABAqOvMBzzVjKgaRX6xgUQlwgCk2vbPMDeY,NAME_SEARCH,UQrl)"}]},{"publishedOn":{"month":2,"year":2017},"description":"This review presents a synthesis of the population pharmacokinetic models for amikacin described in critically ill patients. The objective was to determine whether there was a consensus on a structural model and which covariates had been identified.\n\nA literature search was conducted from the PubMed database, from its inception up until December 2015, using the following terms: 'amikacin', 'pharmacokinetic(s)', 'population', 'model(ling)' and 'nonlinear mixed effect'. Articles were excluded if they were not pertinent. The reference lists of all selected articles were also evaluated.","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27324191","name":"Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.","publisher":"Clin Pharmacokinet. ","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":4,"day":11,"year":2019},"description":"Tacrolimus, a narrow therapeutic range drug that requires TDM is available into an immediate-release (Prograf, twice daily, TD) and a prolonged-release (Advagraf, once daily, OD) form.\n Its PK has been largely described in renal  but not in liver transplant recipients. \n\n- Develop four population PK models and Bayesian estimators (BEs) to help PK-guided dose individualization using in-parallel parametric and nonparametric approaches for each formulation \n- Determination of the best limited sampling strategies for estimating the area-under-the-curve (AUC)\n- Comparison of the doses required to reach AUC targets were estimated using each BE and the doses obtained using the trapezoidal AUC","url":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full\/10.1111\/bcp.13960","name":"Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations in liver transplant patients","publisher":"Br J of Clin Pharmacol","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":4,"year":2017},"description":" Pathophysiological changes in critically ill patients can result in over and sub-therapeutic concentrations of amikacin (AMK). Our objectives were to characterize the pharmacokinetic of AMK and propose AMK dosing regimens for treatment of respiratory ICU patients according to their renal function and body weight.\n\nPopulation pharmacokinetics of AMK was performed using Pmetrics\u00ae from datacollected for routine therapeutic drug monitoring. 1,000 Monte Carlo simulations were performedaccording to different dosing schemes to calculate the probabilities of target attainment (PTA) of [Peak concentration (CMAX) above 8 times the minimum inhibitory concentration (MIC) and residualconcentration (C0) below 2.5mg\/L] in plasma for a MIC range of 0.25 to 16 \u03bcg\/mL (6) ","url":"https:\/\/www.researchgate.net\/publication\/330292795_Target_attainment_analysis_and_optimal_dosing_of_amikacin_in_respiratory_critical_ill_patients_with_various_renal_functions","name":" Target attainment analysis and optimal dosing of amikacin in respiratory critical ill patients with various renal functions","publisher":"Conference: 27th ECCMID: poster presentation","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":4,"year":2016},"description":"Amikacin (AMK) is a commonly used antibiotic for the treatmentof severe gram negative infections in Intensive Care Unit (ICU) patients. A wideinterindividual variability of AMK pharmacokinetics (PK) parameters is observedin ICU patients and therapeutic drug monitoring (TDM) is usually performed tooptimize AMK dosage regimen. The aim of this study was to develop an AMKpopulation pharmacokinetic model (PKPOP) in patients of respiratory ICU using a nonparametric population based approach.\n\nTDM data were retrospectively collected from ICU patients receiving AMK between May and September 2015 in the North university hospital, Marseille. AMK regimen consisted of a once daily 30-min infusion adjusted to achieve the desired Cmax (60\u201380 mg\/L) and trough levels lower than2.5 mg\/L. AMK plasma concentrations were determined using fluorescence polarization immunoassay (Roche Diagnostic\u00e2). The model was implemented in the Pmetrics software, an R Package for the non-parametric NPAG algorithm [1].Predictive performance was assessed using relative bias and root mean squared error (RMSE).","url":"https:\/\/www.researchgate.net\/publication\/330292568_Nonparametric_population_pharmacokinetic_model_of_Amikacin_in_respiratory_critical_ill_patients","name":"Nonparametric population pharmacokinetic model of Amikacin in respiratory critical ill patients","publisher":"Conference: 11e Congres of SFPT, Nancy - oral presentation","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"name":"D\u00e9veloppement d'un estimateur bay\u00e9sien chez le patient adulte transplant\u00e9 h\u00e9patique de novo trait\u00e9 par Advagraf\u00ae ou Prograf\u00ae","publishedOn":{"month":4,"year":2016},"publisher":"Conference: 12e Congres of SFPT Rouen  - oral presentation","url":"https:\/\/www.researchgate.net\/publication\/330292610_Developpement_d%27un_estimateur_bayesien_chez_le_patient_adulte_transplante_hepatique_de_novo_traite_par_AdvagrafR_ou_PrografR","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"name":"Development of a Bayesian estimator based on limited sampling strategies for Advagraf\u00ae and Prograf\u00ae in de novo adult liver transplant patients","publishedOn":{"month":12,"year":2016},"publisher":"Conference: Congr\u00e8s Annuel de la SFT - poster presentation","url":"https:\/\/www.researchgate.net\/publication\/330292835_Development_of_a_Bayesian_estimator_based_on_limited_sampling_strategies_for_AdvagrafR_and_PrografR_in_de_novo_adult_liver_transplant_patients","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":6,"year":2016},"description":"In breast cancer, tumescent lidocaine anaesthesia could increase accessibility to mastectomy in elderly women with comorbidities and relieve post-operative pain. In this procedure, high-dose diluted lidocaine was administrated together with epinephrine [1]. However, few pharmacokinetics data are actually available and potential concentration dependant toxicity was never investigated. We present in this study the first pharmacokinetic model of lidocaine in tumescent anaesthesia for mastectomy with safety and post-operative pain data. \n\nElderly women undergoing total mastectomy were included in this prospective study. A tumescent solution containing 10 mg\/kg of lidocaine 0.1% with epinephrine was infiltrated. Lidocaine serum concentrations were determined using gas chromatography in the course of 48h and were analysis by a population pharmacokinetic approach using NONMEM 7.3. Age, body weight and body mass index (BMI) were investigated as covariates. Side effects, opioid requirement and post-operative pain evaluated by EVA scale were registered.","url":"https:\/\/www.researchgate.net\/publication\/330292505_First_population_pharmacokinetic_model_of_lidocaine_tumescent_anaesthesia_in_women_undergoing_breast_cancer_surgery","name":"First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery","publisher":"Conference: Twenty-fifth PAGE meeting - poster presentation","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":4,"year":2016},"description":"In breast cancer, tumescent lidocaine anaesthesia could increase accessibility to mastectomy in elderly women with comorbidities and relieve postoperative pain. In this procedure, high-dose diluted lidocaine was administrated together with epinephrine [1]. However, few pharmacokinetics data are actually available and potential concentration dependent toxicity was never investigated. We present in this study the first pharmacokinetic model of lidocaine in tumescent anaesthesia for mastectomy with safety and post-operative pain data.\n\nElderly women undergoing total mastectomy were included in this prospective study. A tumescent solution containing 10 mg\/kg of lidocaine 0.1% with epinephrine was infiltrated. Lidocaine serum concentrations were determined using gas chromatography in the course of 48 h and were analysis by a population pharmacokinetic approach using NONMEM 7.3. Age, bodyweight and body mass index (BMI) were investigated as covariates. Side effects, opioid requirement and post-operative pain evaluated by EVA scale were registered","url":"https:\/\/www.researchgate.net\/publication\/330292494_First_population_pharmacokinetic_model_of_lidocaine_tumescent_anaesthesia_in_women_undergoing_breast_cancer_surgery","name":"First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery","publisher":"Conference: 11e Congres of SFPT, Nancy - poster presentation","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":4,"year":2015},"description":"Aminoglycosides (AGs) are major antibiotics used in numerousindications, notably in probabilistic treatment. AGs exhibit a concentration-dependent bactericidal activity, with a post-antibiotic effect. The aim of this retro-spective study was to determine whether the PK\/PD objectives (Cmax\/MIC>8\u201310)were achieved when ANSM recommendations concerning AGs were applied inan intensive care unit (single daily dose at the dosage of 15\u201330 mg\/kg\/day and3\u20138 mg\/kg\/day for amikacin and gentamycin-tobramycin respectively).\n\nA retrospective study was performed during two yearsin the Clinical Pharmacology Unit (Timone Hospital, Marseille), reviewing AGspeak concentrations (Cmax) of patients treated for respiratory or severe infectionsin an intensive care unit. The dosage protocol used was 25 mg\/kg\/day for amika-cin and 8 mg\/kg\/day for gentamicin and tobramycin in a single daily dose. TDMwas systematically performed to evaluate the efficiency and the toxicity of thetreatment (respectively with plasmatic Cmax determination 30 min after the endof the infusion and plasmatic Cmin determination evaluated before the nextadministration). The Cmax targets ranged from 30 to 40lg\/mL for gentamicinand tobramycin and from 60 to 80lg\/mL for amikacin (according to EUCASTunrelated species breakpoint of 4lg\/mL and 8lg\/mL respectively). For documented infections, target ranges were then adapted to specific bacterial breakpoint.\n","url":"https:\/\/www.researchgate.net\/publication\/330292729_Posologies_d%27aminosides_en_reanimation_les_recommandations_de_l%27ANSM_sont-elles_encore_adaptees","name":"Posologies d\u2019aminosides en r\u00e9animation : les recommandations de l\u2019ANSM sont-elles encore adapt\u00e9es ?","publisher":"Conference: 10e Congres of SFPT, Caen - poster presentation","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":9,"year":2020},"description":"Sparse PK assess using NCA (Phoenix WinNonlin)\n","url":"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(20)40670-2\/fulltext","name":"Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib\/II trial in patients (pts) failing prior PD-1\/PD-L1 treatment","publisher":"Annals of Oncology ","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":1,"year":2020},"description":"- Iohexol pharmacokinetics modeling (NONMEM)\n- Bayesian estimator development\n- Comparison of simplified formulas with Bayesian estimator \n","url":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/58\/4\/article-p577.xml","name":"Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance","publisher":"Clinical Chemistry and Laboratory Medicine","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"name":"Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia","publishedOn":{"month":6,"day":10,"year":2019},"publisher":"Page meeting - poster","url":"https:\/\/www.page-meeting.org\/default.asp?abstract=9174","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"name":"Local Anesthetic Plasma Concentrations as a Valuable Tool to Confirm the Diagnosis of Local Anesthetic Systemic Toxicity? A Report of 10 Years of Experience","publishedOn":{"month":3,"day":26,"year":2022},"publisher":"Pharmaceutics","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35456542\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]},{"publishedOn":{"month":9,"day":30,"year":2022},"description":"Therapeutic drug monitoring and treatment optimization of clozapine are recommended, owing to its narrow therapeutic range and pharmacokinetic (PK) variability. This study aims to assess the clinical applicability of published population PK models by testing their predictive performance in an external data set and to determine the effectiveness of Bayesian forecasting (BF) for clozapine treatment optimization.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35385439\/","name":"Towards Precision Dosing of Clozapine in Schizophrenia: External Evaluation of Population Pharmacokinetic Models and Bayesian Forecasting","publisher":"Ther Drug Monit","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABRp8UYBYpsVoDNbIF4ST9RK0Hw1ppENdLY,NAME_SEARCH,RlIq)"}]}],"positions":null,"posts":[{"createdAt":1713529980000,"insightId":"235d676e-9072-4675-b066-bf714f62d62d","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":8}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7187065815353970688","threadUrn":"urn:li:activity:7187065815353970688","reactionsCount":8,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7187065814599041025","message":{"attributes":[{"start":11,"length":40,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:29785"}}},{"start":471,"length":10,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:32979"}}}],"text":"Last\u00a0week, American Association for Cancer Research in San Diego, California witnessed the presentation of the results of the Debio1143-107 study. This study has led to a significant improvement in patient care, as patients with resected, locally advanced squamous cell carcinoma of the head and neck included in the ongoing phase 3 XRay Vision study can now take Xevinapant without regard to food and with Proton Pump Inhibitors.\n\nThank you to my former colleagues from Debiopharm"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQH-_H5v3jtFow\/feedshare-shrink_2048_1536\/0\/1713458161321?e=1720051200&v=beta&t=V6SRWPJUjBcY6HbmAd8He7SeGGf3_BELQGbYAQS_zSU"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7186764421463965696","message":{"attributes":[{"start":77,"length":40,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:29785"}}},{"start":190,"length":10,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:32979"}}},{"start":205,"length":16,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:4235"}}},{"start":295,"length":29,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:23383857"}}},{"start":325,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:342487366"}}},{"start":338,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:254648481"}}},{"start":353,"length":17,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:168603766"}}},{"start":371,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:96484765"}}},{"start":384,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:872472545"}}},{"start":395,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:12501595"}}},{"start":406,"length":17,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:199816186"}}},{"start":424,"length":17,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:11977571"}}},{"start":442,"length":18,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:82381309"}}},{"start":462,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:66847864"}}},{"start":480,"length":21,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:clinicalpharmacology"}}},{"start":502,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:oncology"}}}],"text":"I was excited to present the latest xevinapant clinical pharmacology data at American Association for Cancer Research Conference 2024 last week! Grateful for the ongoing partnership between Debiopharm and Merck Healthcare to make a difference in the lives of patients with head and neck cancer.\nElisabeth Rouits, PharmD, PhD Camille Riff Dany Spaggiari Norbert Wiedemann Pierre COLIN Eleanor H. Raf Crabb\u00e9 Heidi Nauwelaerts Andreas Schroeder Carolina Haefliger  Yulia Vugmeyster \n#clinicalpharmacology #oncology"},"entityUrn":"urn:li:share:7186764421463965696"},"entityUrn":"urn:li:share:7187065814599041025"}}},{"createdAt":1713162420000,"insightId":"c6b15bfe-4919-4b8e-a1a2-cbe11cd5174d","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":5},{"type":"EMPATHY","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7185524154354270208","threadUrn":"urn:li:ugcPost:7185524154354270208","reactionsCount":7,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7185524154354270208","message":{"attributes":[{"start":56,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:5837010"}}},{"start":244,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:5837010"}}},{"start":390,"length":12,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:71391545"}}},{"start":438,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:joinjci"}}},{"start":447,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:leardership"}}},{"start":460,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:lifelonglearning"}}},{"start":478,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:debating"}}},{"start":488,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:jci"}}}],"text":"Yesterday, I had the privilege to receive a training by Fredrik Bergfors the World Champion JCI 2015 in Debating. \n\nA session full of learning, fun, excitement, vulnerability, challenges where my adrenaline level was high \ud83d\ude0a \nThank you so much Fredrik Bergfors for sharing your experience, and the board for organizing this training.\n\u00a0\nPlease reach out to me if you want to know more about JCI G\u00f6teborg and join us for the next training\n\n#joinJCI #leardership #lifelonglearning\u00a0#debating #JCI"},"rootActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:event:7178126289218793472"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7178126291332718592","message":{"attributes":[],"text":""},"entityUrn":"urn:li:ugcPost:7178126291332718592"},"entityUrn":"urn:li:ugcPost:7185524154354270208"}}},{"createdAt":1712946120000,"insightId":"6ac96732-9963-4f57-90c6-18019d0c2c93","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7184616825727406080","threadUrn":"urn:li:activity:7184616825727406080","reactionsCount":1,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184616825198903296","message":{"attributes":[],"text":"Pharmacists are well known as the final gatekeeper to ensure that patients received the right treatment at the right dose and that they understand their illness and treatment.\n\nPleased to see such of initiative that extents the vital role of pharmacists in early cancer detection."},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQFk3uU1narZbQ\/image-shrink_1280\/0\/1712572355768?e=1717977600&v=beta&t=ycm3zkK0RdltZsmFhoW1f8DVjIh6U2wIdoOb81uTmHA","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQFk3uU1narZbQ\/image-shrink_1280\/0\/1712572355768?e=1717977600&v=beta&t=ycm3zkK0RdltZsmFhoW1f8DVjIh6U2wIdoOb81uTmHA"}]},"description":"Around three million people in the UK were estimated to be living with cancer in 2022","resolvedUrl":"http:\/\/dlvr.it\/T5D4Kt","title":"Alliance Healthcare launches cancer symptom referral scheme in UK pharmacies - PharmaTimes"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7183049082423123968","message":{"attributes":[{"start":164,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:news"}}},{"start":170,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:alliancehealthcare"}}},{"start":190,"length":23,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:alphegapharmaceuticals"}}}],"text":"Alliance Healthcare launches cancer symptom referral scheme in UK pharmacies: Around three million people in the UK were estimated to be living with cancer in 2022 #News #AllianceHealthcare #AlphegaPharmaceuticals"},"entityUrn":"urn:li:share:7183049082423123968"},"entityUrn":"urn:li:share:7184616825198903296"}}},{"createdAt":1712945220000,"insightId":"0099e7c1-c2fb-41ce-81da-a026203cdfc1","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":3}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7184613134119137281","threadUrn":"urn:li:activity:7184613134119137281","reactionsCount":3,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184613133569642496","message":{"attributes":[],"text":"Medical affairs teams play a crucial role in driving impactful transformation in today's healthcare landscape, but how to demonstrate their value? by better measuring impact, be open to change and embracing emerging technologies like AI and machine learning.  "},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQE7tCax6Ca_9A\/image-shrink_1280\/0\/1712918179185?e=1717977600&v=beta&t=cG9DOZYSKoDha3FMoKZrUHiWHUZw8udduBCHNvreyMQ","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQE7tCax6Ca_9A\/image-shrink_1280\/0\/1712918179185?e=1717977600&v=beta&t=cG9DOZYSKoDha3FMoKZrUHiWHUZw8udduBCHNvreyMQ"}]},"description":"Navigating healthcare landscapes and measuring impact in medical affairs","resolvedUrl":"http:\/\/dlvr.it\/T5Pt0L","title":"Driving transformation - PharmaTimes"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184499571471851521","message":{"attributes":[{"start":97,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:webexclusives"}}}],"text":"Driving transformation: Navigating healthcare landscapes and measuring impact in medical affairs #WebExclusives"},"entityUrn":"urn:li:share:7184499571471851521"},"entityUrn":"urn:li:share:7184613133569642496"}}},{"createdAt":1712733420000,"insightId":"58b32d2e-85f7-4347-8a21-75f63ffd96d5","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":8},{"type":"APPRECIATION","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7183724714098331649","threadUrn":"urn:li:activity:7183724714098331649","reactionsCount":9,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7183724713624391681","message":{"attributes":[],"text":"Are you a road cyclist in Gothenburg area and want to join us?\n\nHere you have a friendly and challenging environment!"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D5622AQFx76FJt5zIVw\/feedshare-shrink_2048_1536\/0\/1712726277404?e=1720051200&v=beta&t=GTP19sC3WXP8NelSH0fBZEyJOvfDou-2XGUcSgXUVhM"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7183694682101624832","message":{"attributes":[{"start":94,"length":13,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:70931098"}}},{"start":343,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:3821894"}}}],"text":"Road cyclist + Working in life sciences + Gothenburg based?\n\nWe're planning our spring\/summer BiotechBikers rides in Gothenburg and want to find even more people who like cycling and work in life sciences, to come and join us!\n\nIf you match the description, or know someone who does, please let me (looking a bit surprised in black below!) or Fredrik R\u00f6\u00f6k (behind the camera) know, so we can add you to the invite list. "},"entityUrn":"urn:li:share:7183694682101624832"},"entityUrn":"urn:li:share:7183724713624391681"}}},{"createdAt":1711045560000,"insightId":"5acb573c-f792-43a3-8503-d0a4d7e026fd","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":6}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7176645248264110081","threadUrn":"urn:li:activity:7176645248264110081","reactionsCount":6,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7176645247534280704","message":{"attributes":[{"start":128,"length":17,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:8624942"}}}],"text":"\ud83c\udf1fLooking for an opportunity to apply your clinical pharmacology expertise on CVRM projects? \n\nHave a look on this job offer in Angelica Quartino\u2019s team. \n\n\ud83e\udd14And please reach out to me if you have any questions."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D22AQEX1iE6p-fWsg\/feedshare-shrink_2048_1536\/0\/1710837902664?e=1720051200&v=beta&t=3_U9pII0JUDVczkIRKyWyTkAIKn4oXFTtGTwYkGw_IQ"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7175774263642124288","message":{"attributes":[{"start":336,"length":17,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:8624942"}}},{"start":424,"length":11,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1603"}}},{"start":704,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/dFsmtdwv"}}},{"start":731,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:astrazeneca"}}},{"start":744,"length":21,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:clinicalpharmacology"}}},{"start":766,"length":25,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:quantitativepharmacology"}}},{"start":792,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharmacokinetics"}}},{"start":810,"length":20,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:clinicaldevelopment"}}},{"start":831,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:gothenburg"}}},{"start":843,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:greatplacetowork"}}}],"text":"Do you have expertise and experience in clinical pharmacology, PK, PKPD, Model Informed Drug Development and its application in drug development and would like to apply your expertise in a company that is following the science and turn ideas into life changing medicines?\n\u00a0\nWe are now looking for a Clinical Pharmacology Expert to join Angelica Quartino's skilled Clinical Pharmacology and Quantitative Pharmacology team at AstraZeneca at our vibrant\u00a0Gothenburg site in Sweden. This is a global role that will support large- and small molecule projects across all phases of clinical development within the therapy area of\u00a0Cardiovascular, Renal and Metabolism.\u00a0\n\u00a0\nRead more about the role and apply here:\u00a0https:\/\/lnkd.in\/dFsmtdwv\n\u00a0\n#astrazeneca #clinicalpharmacology #quantitativepharmacology #pharmacokinetics #clinicaldevelopment #gothenburg #greatplacetowork"},"entityUrn":"urn:li:share:7175774263642124288"},"entityUrn":"urn:li:share:7176645247534280704"}}},{"createdAt":1711010160000,"insightId":"f4c20776-5b45-473f-aa1d-88cded17b5d8","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7176496765125185537","threadUrn":"urn:li:ugcPost:7176496765125185537","reactionsCount":2,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7176496765125185537","message":{"attributes":[],"text":"The next FDA's Webinar will discuss how to Navigate FDA's Drug Information Resources. Sounds an interesting topic to stay up to date and learn how to get access to meaningful information quickly.\nJoin me on March 26."},"rootActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:event:7171170092615909378"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171170095807750144","message":{"attributes":[],"text":"Join us for our free CE webinar on March 26 at 1:00 PM ET, to learn about FDA's drug information resources, identify tools to stay informed, and more."},"entityUrn":"urn:li:ugcPost:7171170095807750144"},"entityUrn":"urn:li:ugcPost:7176496765125185537"}}},{"createdAt":1710775260000,"insightId":"5143239f-f7a1-4de8-8831-e01733f12c7c","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":3}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7175511629625753600","threadUrn":"urn:li:activity:7175511629625753600","reactionsCount":3,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7175511629139169282","message":{"attributes":[{"start":510,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:fightcancer"}}},{"start":523,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancerawareness"}}},{"start":540,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancerprevention"}}},{"start":558,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancertherapy"}}}],"text":"R\u00e9sum\u00e9 interessant de la situation francaise dans la lutte contre le cancer. \n\nQuelques chiffres important:\n\ud83d\udc40  40 % des cancers sont \u00e9vitables\n\ud83d\udc40  Le nombre de nouveaux cas de cancers a doubl\u00e9, avec une augmentation de 98 % des cancers chez l'homme et de 104 % chez la femme, en 33 ans. Hausse li\u00e9e au vieillessement de la population et aux comportements et modes de vie.\n\nLa France est leader dans la recherche contre le cancer dans le monde notamment en facilitant l\u00b4acc\u00e8s \u00e0 des th\u00e9rapies innovantes ! \ud83d\udcaa \n\n#fightcancer #cancerawareness #cancerprevention #cancertherapy \n"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQHU4Jkw_N3ySg\/articleshare-shrink_800\/0\/1711970090472?e=1717977600&v=beta&t=U1fvvCg94r0_kMxmG1900LcAAk_yh1iYl1mL1UePvc8","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQHU4Jkw_N3ySg\/articleshare-shrink_800\/0\/1711970090472?e=1717977600&v=beta&t=U1fvvCg94r0_kMxmG1900LcAAk_yh1iYl1mL1UePvc8"}]},"description":"Aujourd\u2019hui, nombre de cancers sont gu\u00e9ris et la mortalit\u00e9 continue de baisser gr\u00e2ce \u00e0 des diagnostics plus pr\u00e9coces et \u00e0 des traitements plus efficaces et plus cibl\u00e9s. On assiste aussi \u00e0 l\u2019essor des traitements \u00ab sur mesure \u00bb gr\u00e2ce \u00e0 une connaissance...","fullText":"\u25cf\u00a0\u00a0 On estime \u00e0 433 136 le nombre de nouveaux cas de cancers en 2023 en France 1 . Chez les hommes, les trois cancers les plus fr\u00e9quents sont ceux de la prostate, du poumon et du c\u00f4lon-rectum. Chez les femmes, ce sont les cancers du sein, du c\u00f4lon-rectum et du poumon. \u25cf\u00a0\u00a0 Entre 1990 et 2023, le nombre de nouveaux cas de cancers a doubl\u00e9, avec une augmentation de 98 % des cancers chez l'homme et de 104 % chez la femme, toutes localisations confondues 1 La hausse de l'incidence des cancers serait li\u00e9e dans une large mesure \u00e0 l'\u00e9volution d\u00e9mographique de la France (accroissement et vieillissement de la population), mais aussi \u00e0 une hausse du risque li\u00e9 aux comportements et modes de vie. \u25cf\u00a0\u00a0 La mortalit\u00e9 par cancer a diminu\u00e9 de 2 % par an chez les hommes et de 0,7 % par an chez les femmes entre 2010 et 2018. La proportion des personnes qui survivent apr\u00e8s un cancer augmente globalement en France, malgr\u00e9 des diff\u00e9rences selon la localisation de la maladie, selon une \u00e9tude de Sant\u00e9 Publique France de juillet 2021 . Parmi les cancers les plus fr\u00e9quents, une augmentation significative de la survie nette \u00e0 5 ans est observ\u00e9e pour le cancer du sein (88% des malades survivent apr\u00e8s cette p\u00e9riode), les cancers du c\u00f4lon et du rectum (63%) et le cancer du poumon, qui reste toutefois une maladie \u00e0 \"pronostic d\u00e9favorable\" (20% de survie \u00e0 5 ans). \u25cf\u00a0 \u00a060 % des cancers du sein, 44 % des cancers du c\u00f4lon et 47 % des cancers du rectum sont d\u00e9pist\u00e9s \u00e0 un stade pr\u00e9coce. (2) \u25cf\u00a0\u00a0 En France, la recherche en canc\u00e9rologie est l\u2019une des plus actives au monde. Elle est soutenue par une volont\u00e9 politique forte, qui s\u2019est exprim\u00e9e d\u00e8s 2003 avec le lancement du premier plan cancer par Jacques Chirac, puis des trois suivants. Cette volont\u00e9 s\u2019est traduite, entre autres mesures, par la cr\u00e9ation en 2005 de l\u2019Institut national du cancer (INCa). \u25cf\u00a0 Pour contribuer \u00e0 acc\u00e9l\u00e9rer l\u2019\u00e9mergence de l\u2019innovation au b\u00e9n\u00e9fice des patients, la France met en place, depuis 2013, des essais cliniques d\u2019un nouveau type dans le cadre du programme AcS\u00e9 (Acc\u00e8s s\u00e9curis\u00e9 \u00e0 des th\u00e9rapies cibl\u00e9es innovantes). Ce dernier vise \u00e0 proposer et s\u00e9curiser l\u2019acc\u00e8s hors autorisation de mise sur le march\u00e9 (AMM) \u00e0 des th\u00e9rapies cibl\u00e9es pour lesquelles une indication existe d\u00e9j\u00e0 dans un autre organe.","resolvedUrl":"https:\/\/www.leem.org\/100-questions\/cancers-vers-une-connaissance-de-plus-en-plus-fine","title":"Cancers : vers une connaissance de plus en plus fine ?","sourceDomain":"leem.org"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7175449612336410624","message":{"attributes":[{"start":37,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancer"}}},{"start":449,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancerdusein"}}},{"start":705,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/gfvTdtZp"}}}],"text":"Semaine nationale de lutte contre le #cancer : aujourd\u2019hui, nombre de cancers sont gu\u00e9ris et la mortalit\u00e9 continue de baisser gr\u00e2ce \u00e0 des diagnostics plus pr\u00e9coces et \u00e0 des traitements plus efficaces et plus cibl\u00e9s. \ud83d\ude4f On assiste aussi \u00e0 l\u2019essor des traitements \u00ab sur mesure \u00bb via une connaissance plus pointue des tumeurs.\n \n\nParmi les cancers les plus fr\u00e9quents, une augmentation significative de la survie nette \u00e0 5 ans est observ\u00e9e pour :\n\n- le #cancerdusein (88% des malades survivent apr\u00e8s cette p\u00e9riode)\n\n- les cancers du c\u00f4lon et du rectum (63%)\n\n- le cancer du poumon, qui reste toutefois une maladie \u00e0 \"pronostic d\u00e9favorable\" (20% de survie \u00e0 5 ans).\n\n \n\u27a1\ufe0f Un objectif : \u00e9radiquer le cancer. \ud83d\udc49 https:\/\/lnkd.in\/gfvTdtZp"},"entityUrn":"urn:li:share:7175449612336410624"},"entityUrn":"urn:li:share:7175511629139169282"}}},{"createdAt":1710139860000,"insightId":"48d12f96-64ef-422a-9135-fae2a7bf4151","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":12},{"type":"PRAISE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7172846578297196544","threadUrn":"urn:li:activity:7172846578297196544","reactionsCount":13,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7172846577651302403","message":{"attributes":[],"text":"Do you know that you can find this material on FDA website that explains the FDA Drug Approval Process?\n\nNice pictures and clear explanations about the long and expensive process of developing effective and safe drugs for the patients."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D22AQFNWxU9k8qvzA\/feedshare-shrink_2048_1536\/0\/1708256939118?e=1720051200&v=beta&t=ykUxu2UdnOrKJZZ3po1shG6Ax5eBzeKQSseVHaz_3jo"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7164948914570301441","message":{"attributes":[{"start":88,"length":3,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:4652"}}},{"start":515,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/dUfMMD78"}}},{"start":541,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:fda"}}},{"start":546,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:nda"}}},{"start":551,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:ind"}}},{"start":556,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharma"}}},{"start":564,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":581,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womeninbusiness"}}},{"start":598,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drjojo"}}}],"text":"\u2705 \ud835\udc05\ud835\udc03\ud835\udc00 \ud835\udc1d\ud835\udc2b\ud835\udc2e\ud835\udc20 \ud835\udc1a\ud835\udc29\ud835\udc29\ud835\udc2b\ud835\udc28\ud835\udc2f\ud835\udc1a\ud835\udc25 \ud835\udc29\ud835\udc2b\ud835\udc28\ud835\udc1c\ud835\udc1e\ud835\udc2c\ud835\udc2c\n\nA great infographic developed by the FDA summarising the drug approval process:\n\n1\ufe0f\u20e3 \ud835\udc0f\ud835\udc2b\ud835\udc1e-\ud835\udc1c\ud835\udc25\ud835\udc22\ud835\udc27\ud835\udc22\ud835\udc1c\ud835\udc1a\ud835\udc25:\n\u2686\u00a0Drug development\n\u2686 Animal testing\n\u2686 IND application\n\n2\ufe0f\u20e3 \ud835\udc02\ud835\udc25\ud835\udc22\ud835\udc27\ud835\udc22\ud835\udc1c\ud835\udc1a\ud835\udc25 \ud835\udc2d\ud835\udc2b\ud835\udc22\ud835\udc1a\ud835\udc25\ud835\udc2c:\n\u2686 Phase I\n\u2686 Phase II\n\u2686 Phase III\n\n3\ufe0f\u20e3\u00a0\ud835\udc0d\ud835\udc03\ud835\udc00 (\ud835\udc0d\ud835\udc1e\ud835\udc30 \ud835\udc03\ud835\udc2b\ud835\udc2e\ud835\udc20 \ud835\udc00\ud835\udc29\ud835\udc29\ud835\udc25\ud835\udc22\ud835\udc1c\ud835\udc1a\ud835\udc2d\ud835\udc22\ud835\udc28\ud835\udc27) \ud835\udc2b\ud835\udc1e\ud835\udc2f\ud835\udc22\ud835\udc1e\ud835\udc30:\n\u2686 Review meeting\n\u2686 NDA application\n\u2686 Application reviewed\n\u2686 Drug labelling\n\u2686 Facility inspection\n\n4\ufe0f\u20e3\u00a0\ud835\udc0f\ud835\udc28\ud835\udc2c\ud835\udc2d-\ud835\udc26\ud835\udc1a\ud835\udc2b\ud835\udc24\ud835\udc1e\ud835\udc2d\ud835\udc22\ud835\udc27\ud835\udc20 \ud835\udc2c\ud835\udc2e\ud835\udc2b\ud835\udc2f\ud835\udc1e\ud835\udc22\ud835\udc25\ud835\udc25\ud835\udc1a\ud835\udc27\ud835\udc1c\ud835\udc1e\n\nSource: https:\/\/lnkd.in\/dUfMMD78\n\n#fda #nda #ind #pharma #drugdevelopment #womeninbusiness #drjojo"},"entityUrn":"urn:li:share:7164948914570301441"},"entityUrn":"urn:li:share:7172846577651302403"}}},{"createdAt":1709813820000,"insightId":"15935fd9-ffe1-4581-b7d7-2adae2b3a475","activityUnion":{"postActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:celebrateCertificate:7171479081631367168"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":32},{"type":"PRAISE","count":8},{"type":"EMPATHY","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7171479082835124225","threadUrn":"urn:li:ugcPost:7171479082835124225","reactionsCount":42,"commentsCount":4,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171479082835124225","message":{"attributes":[{"start":271,"length":9,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:5383"}}}],"text":"Artificial Intelligence is everywhere and is key to improve the way we work. I am pleased to say that AstraZeneca supports me developing my skills. \n\nI\u2019m happy to share that I\u2019ve obtained a new certification: Transforming the Workplace Using Artificial Intelligence from Skillsoft!"},"entityUrn":"urn:li:ugcPost:7171479082835124225"}}},{"createdAt":1709576040000,"insightId":"524fadab-2a51-4912-9818-9b40860689f9","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQHi3O9aXdrQPA\/articleshare-shrink_800\/0\/1711645907728?e=1717977600&v=beta&t=mcUuS8JdMj-EUAB2V1oFpGt038a1xHCfVgmrl3yLD4Y","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQHi3O9aXdrQPA\/articleshare-shrink_800\/0\/1711645907728?e=1717977600&v=beta&t=mcUuS8JdMj-EUAB2V1oFpGt038a1xHCfVgmrl3yLD4Y"}]},"description":"Eiffel Tower lit up to mark change, seen as way of protecting law that decriminalised abortion in 1975","resolvedUrl":"https:\/\/amp-theguardian-com.cdn.ampproject.org\/c\/s\/amp.theguardian.com\/world\/2024\/mar\/04\/france-to-hold-final-vote-on-enshrining-abortion-as-a-constitutional-right","title":"France makes abortion a constitutional right in historic Versailles vote"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":22}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7170481802669723649","threadUrn":"urn:li:activity:7170481802669723649","reactionsCount":22,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7170481801906343936","message":{"attributes":[],"text":"Big step to support women\u2019s right today! "},"entityUrn":"urn:li:share:7170481801906343936"}}},{"createdAt":1716660180000,"insightId":"9816fbb0-da19-413a-b9b2-2e63e05efb8f","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7200165344290701312,7200194752980430848)","threadUrn":"urn:li:ugcPost:7200165344290701312","reactionsCount":0,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Francesco"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7200165344290701312"}}},{"createdAt":1713159540000,"insightId":"8c2062c3-e53e-47ad-9a78-f6b96bf17180","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1},{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7185257576765235200,7185511922228678656)","threadUrn":"urn:li:ugcPost:7185257576765235200","reactionsCount":2,"commentsCount":1,"canComment":true},"commentary":{"attributes":[{"start":17,"length":18,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:3282743"}}}],"text":"Very good advice Maaike Addicks, MD ! \nYou highlight very well the importance of Feeling grateful and showing you are grateful to the people around you! Those are the people that makes you doing a great job."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7185257576765235200"}}},{"createdAt":1713159240000,"insightId":"95a5ef21-357d-4748-a486-6c075e5d4616","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7185374994028281857,7185510828823969792)","threadUrn":"urn:li:ugcPost:7185374994028281857","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrat Noha. So great to have you in the AZ Clinical Pharmacology community! \nWelcome and please reach out if I can be of any help."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7185374994028281857"}}},{"createdAt":1712733060000,"insightId":"50ae1a32-f665-4301-aad8-25ed952435a8","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7183703028997193728,7183723310772322304)","threadUrn":"urn:li:ugcPost:7183703028997193728","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":33,"length":18,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:132716425"}}}],"text":"Congratulations and best of luck Justyna Nowakowska"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7183703028997193728"}}},{"createdAt":1712687340000,"insightId":"f0c662b0-1a93-4e8f-9e45-079e8565c12c","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7183430076640727041,7183531499323826176)","threadUrn":"urn:li:ugcPost:7183430076640727041","reactionsCount":0,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Exciting! Congratulation Guillaume! Can't wait to know more about"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7183430076640727041"}}},{"createdAt":1712647920000,"insightId":"9c1fc38f-1074-49cf-963d-ed51e448a528","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7181580989784018945,7183366044713943041)","threadUrn":"urn:li:activity:7181580989784018945","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Best wishes to both of you"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7181580989784018945"}}},{"createdAt":1712169060000,"insightId":"717c5054-8a47-46f4-a143-debaf3a157d5","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7181348344080793602,7181357605095641089)","threadUrn":"urn:li:ugcPost:7181348344080793602","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Well done with the Guidance snapshot!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181348344080793602"}}},{"createdAt":1712077860000,"insightId":"254a764e-3dbd-4292-9eea-52218954c1c9","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7180374571622023169,7180975098537893890)","threadUrn":"urn:li:activity:7180374571622023169","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":186,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:218691083"}}}],"text":"My favorite book and the one I shared recently with a colleague who wanted to know more about clinical pharmacology and pharmacometrics. \nVery comprehensive book to keep on your desk. \n\nAdrian Olszewski great challenge to read the entire book! \u00a0You've got this!  "},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7180374571622023169"}}},{"createdAt":1711000080000,"insightId":"2b57c70d-cbcd-4ae3-bd56-25e88ad96ff5","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7176289581758054400,7176454602748231680)","threadUrn":"urn:li:ugcPost:7176289581758054400","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":6,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:222652890"}}}],"text":"Bravo Alexandre Drezet !"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7176289581758054400"}}}]}